RecruitingNCT04324164
Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC
Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced Non-small Cell Lung Cancer in China
Sponsor
Hunan Province Tumor Hospital
Enrollment
800 participants
Start Date
Mar 24, 2020
Study Type
OBSERVATIONAL
Conditions
Summary
This study aims to explore Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced Non-small Cell Lung Cancer in China
Eligibility
Min Age: 18 Years
Inclusion Criteria2
- ，Advanced Non-squamous Non-small Cell Lung Cancer Confirmed by Histopathology
- Uncommon EGFR Mutant Advanced NSCLC
Exclusion Criteria2
- Patients with contraindication of chemotherapy
- Pregnant or breast feeding women
Interventions
DRUGThird-generation EGFR-TKI
Third-generation EGFR-TKI including Osimertinib/Furmonertinib/Almonertinib, etc.
DRUGEGFR-TKI
All EGFR-TKI
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04324164
Related Trials
Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
NCT07195695192 locations
An Observational Study to Assess the Effectiveness and Safety of a Cemiplimab in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in Europe
NCT0536331949 locations
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
NCT0711504311 locations
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
NCT06712316184 locations
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
NCT06345729212 locations